Diabetes, Heart and Cardiovascular Diseases News Chronicle Diabetes, Cardiovascular and Heart Diseases. Article 325
Published on April 19, 2018 at 11:30 AM GMT


Re-categorization of diabetes into five clusters for a precise diabetes diagnosis and an individualized treatment


Re-categorization of diabetes into SAID, SIDD, SIRD, MOD and MARD for an early treatment of diabetes.

With the current diabetes classification and guidelines, a healthcare professional can not forecast precisely which patient require intensified diabetes treatment and how to control a newly diagnosed diabetes patient with high blood sugar or glucose levels. Currently, diabetes is categorized as

In a study intended to find out precise diabetes diagnosis and individualized diabetes treatment, researchers from Sweden and Finland led by the experts from the Lund University, Lund, Scania, Sweden have suggested re-categorization of diabetes.


Researchers have conducted studies on 13,270 newly diagnosed diabetes patients aged between 18 to 97 years. They says diabetes can be reclassified based on physiological and genetic profiles into three severe diabetes clusters and two mild diabetes clusters. They also studied diabetes development and available treatment options to the newly diagnosed patients. One of the newly reclassified cluster is similar to type 1 diabetes and the other four clusters are subtypes of type 2 diabetes. Researchers isolated following parameters during the reclassification studies.

Researchers have observed following during their study.

Cluster name Researchers observation
Cluster 1
Severe autoimmune diabetes (SAID)
  • Patients are found to be with highest levels of HbA1c (or blood sugar or glucose levels) in the bloodstream.
  • About 31 percent likely presence of ketoacidosis at diagnosis compared to patients in cluster 3, 4 and 5.
  • About 42 percent of the patients are using insulin.
  • Lowest number of patients are using metformin.
Cluster 2
Severe insulin-deficient diabetes (SIDD)
  • Patients are found to be with highest levels of HbA1c (or blood sugar or glucose levels) in the bloodstream.
  • About 25 percent likely presence of ketoacidosis at diagnosis compared to patients in cluster 3, 4 and 5.
  • About 29 percent of the patients are using insulin.
  • Maximum number of patients are using metformin.
  • Patients in this cluster are at highest risk to the development of diabetic retinopathy.
Cluster 3
Severe-insulin resistant diabetes (SIRD)
  • Usage of insulin is less than 4 percent.
  • Lowest number of patients are using metformin.
  • Patients in this cluster are at highest risk to the development of diabetic nephropathy and chronic diseases.
  • Patients are with modest increase in urine albumin (a risk to kidney disease). People in this cluster are at higher risk of end-stage renal disease.
Cluster 4
Mild obesity-related diabetes (MOD)
  • Usage of insulin is less than 4 percent.
Cluster 5
Mild age-related diabetes (MARD)
  • Usage of insulin is less than 4 percent.


In the new diabetes classification, researchers have proposed following diabetes clusters for a precise diabetes diagnosis and an individualized treatment.

Cluster name Characteristics of the diabetes patient in the cluster
Cluster 1
Severe autoimmune diabetes (SAID)
  • An autoimmune condition, where beta cells in pancreas could not able to produce sufficient insulin to maintain sugar or glucose levels in the bloodstream.
  • Presence of glutamic acid decarboxylase (GAD) antibodies in the bloodstream.
  • Diabetes condition with highest levels of HbA1c (or blood sugar or glucose levels) in the bloodstream.
  • Corresponds to type 1 diabetes and latent autoimmune diabetes of adults LADA (or unofficially called as type 1.5 diabetes).
  • Affected people are relatively low in body mass index (BMI) with poor metabolic control.
  • Affects people at young age.
Cluster 2
Severe insulin-deficient diabetes (SIDD)
  • Patients in this cluster are similar to Cluster 1 (severe autoimmune diabetes SAID), but without glutamic acid decarboxylase (GAD) antibodies in the bloodstream.
  • Diabetes condition arises as beta cells in pancreas fails to produce sufficient insulin.
  • Diabetes condition with highest levels of HbA1c (or blood sugar or glucose levels) in the bloodstream.
  • Highest incidence of retinopathy.
Cluster 3
Severe-insulin resistant diabetes (SIRD)
  • Patients in this cluster are with higher body mass index (BMI).
  • Beta cells in the pancreas produces sufficient insulin required to transfer sugar or glucose along with oxygen from bloodstream to cells. But cells are not responding to insulin calls (condition known as insulin resistance) to absorb glucose.
  • These people are at higher risk to diabetic nephropathy (or diabetic kidney disease).
Cluster 4
Mild obesity-related diabetes (MOD)
  • Patients in this cluster are obese.
  • Younger in age.
  • No insulin resistance.
Cluster 5
Mild age-related diabetes (MARD)
  • Occurs in the people during old age.
  • Diabetes development due to small metabolic changes.

Researchers says their reclassification of diabetes can help healthcare professionals in making better forecast of the risks associated with diabetes in a patient. The reclassification can also help healthcare professionals in providing individualized early treatments. Lead author of the study says they found an evidence which shows life threatening complications associated with diabetes can be prevented with an early treatment of diabetes.

Lead author of the study was Professor Leif Groop, MD, PhD, Lund University - Diabetes Center, Malmoe, Sweden. The study findings were published online March 1, 2018 in The Lancet Diabetes and Endocrinology. Title of the article was "Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables." DOI : doi.org/10.1016/S2213-8587(18)30051-2


       
If you like this article, please share it with a friend! Article address is (copy and past the code below):

Also related to this story
1. Common causes of death in patients with both type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD)
2. Number of complications that may be developed in a type 2 diabetes patient are not linked with the diabetes severity.
3. Muscle cramp events and its frequency and its severity were linked to nerve function in type 1 diabetes, but not type 2 diabetes
4. A new vaccine developed by Scandinavian researchers could prevent type 1 diabetes
5. Ozempic (semaglutide) GLP-1 type 2 diabetes drug from Novo Nordisk can reduce obesity and body fat levels
6. Type 2 diabetes patients with chronic kidney diseases can survive longer with metformin
7. Lower risk to obesity and type 2 diabetes with the consumption of whole grains and milled whole grains
8. Obesity, poverty are the factors for higher type 2 diabetes risk for American Blacks
9. Diet with high magnesium content can prevent type 2 diabetes
10. Higher urea levels or reduced kidney functionality can increase diabetes risk
11. Higher risk to hospitalization or premature death among heart failure patients with diabetes.
12. Researchers identified link between obesity and type 2 diabetes
13. Longer breastfeeding decreases type 2 diabetes risk for mothers
14. Insulin pills may delay onset of type 1 diabetes in some individuals
15. Type 2 diabetes protection with antioxidant foods containing Vitamin C & E, lycopenes or flavonoids
16. TRAFFIC, a Retrievable and Scalable Cell Encapsulation Device for the treatment of type 1 diabetes

Glutamic acid decarboxylase : Glutamic acid decarboxylase is an enzyme. Our pancreas requires this enzyme for the normal functioning of the pancreas. By mistake, our immune system makes antibodies to attack glutamic acid decarboxylase enzyme. These antibodies are called GAD antibodies. Studies shows blood of 70 percent of the type 1 diabetes patients carries GAD antibodies.

GAD : See Glutamic acid decarboxylase.

 

Categories

Sitemap 1   Sitemap 2   Sitemap 3   Sitemap 4

 

Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.


Published by Jammi Vasista, Chennai, India.
Email Jammi[no-space]Vasista1991[at]gmail[dot]com
Phone 91-944-578-3182.
Address Diabetes News Chronicle, No 40, Kaveri Street, Rajaji Nagar, Villivakkam, Chennai, India. Pin : 600049.